Drugs / PTgen
last change Sep 2020 re-read 2 minutes ago

PTgen

Developed for
pertussis
Investigated by
DBV Technologies · University Hospital, Geneva

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03035370 Sep 2016 → Apr 2018 pertussis DBV Technologies Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as PTgen “Objectives of this study were to evaluate safety and capacity of a recombinant pertussis toxin (PTgen) -coated Viaskin® epicutaneous patch to recall memory responses in healthy adults.” PMID 32896653 Sep 2020
Route Other “administered via the cutaneous route” NCT03035370